MedTrace Logo

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

NCT03860818 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2196

Last updated 2024-08-01

Study results available
· View outcomes & findings →

Summary

Medication safety issues in Veteran organ transplant recipients, including side effects and errors, are a major issue leading to graft failure and death. The causes of these events are complicated and involve fragmented care, communication breakdowns between the Veterans, providers and the different health care systems. This grant proposal seeks to improve medication safety within these high-risk Veterans, using two innovative components; the application of technology to leverage the massive amount of data contained within the electronic medical record in identifying Veterans with potential medication safety issues, coupled with a pharmacist-led intervention to improve the management and coordination of immunosuppression therapy. The completion of this prospective, multicenter, cluster randomized controlled clinical trial will provide evidence that these interventions can improve medication safety, clinical outcomes and costs and will be used to justify the dissemination of these interventions to all VAs caring for Veteran transplant recipients across the U.S.

Conditions

  • Transplant

Interventions

OTHER

Health services delivery

Technology-enabled pharmacist intervention

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • David J. Taber, PharmD · Ralph H. Johnson VA Medical Center, Charleston, SC

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2021-06-14
Completion
2021-06-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03860818 on ClinicalTrials.gov